XL-147

934526-89-3

XL-147 (Pilaralisib) is a potent, selective and orally bioavailable ATP-competitive small molecule inhibitor targeting pan-class I phosphatidylinositol 3 kinase (PI3K) family with IC50 values of 39, 383, 36 and 23 nM for p110 α , β , δ and γ isoforms, and is highly selective over mTOR (IC50 > 15000 nM), VPS34 (IC50 = 6975 nM), DNAPK (IC50 = 4750 nM). It is currently in clinical trials for cancer treatment.

Store at 0° C (short term), -20° C (long term), desiccated

HPLC-MS, ¹HNMR, Microanalysis (Elemental Analysis)

1. GI Shapiro, et al., Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014 Jan 1; 20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777.

2. CP Reynolds, et al., Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer, 2013 May; 60(5):791-8. doi: 10.1002/pbc.24301.

3. L. Debussche, et al, Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer, EP 2648729 A1 (text from WO2012078832A1)